SMC^® Human cTnI High Sensitivity Immunoassay Kit

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

SMC is a registered trademark of Singulex

FEMTOQUEST is a trademark of Merck KGaA, Darmstadt, Germany

Cardiovascular

• Sensitivity: LLOQ 690 fg/mL* (SMCxPRO^® Instrument)
• Standard Curve Range: 170-600,000 fg/mL
• Intra-assay CV: <15%
• Inter-assay CV: <20%
• Linearity: Serum: 80% Plasma: 85%
• Recovery: Plasma: 119%

*Indicative LLOQ created from average of 14 independent in house runs, where >80% met same value defined with CV & Recovery +/- 20%. Refer to CoA for lot specific performance.

Although cTnI was detectable in non-human primate, mouse, rat, canine and equine samples, the assay has not been verified for these species.

Our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Cardiac Troponin I (cTnI) is a regulatory protein found in cardiac muscle tissue and plays a critical role in muscle contraction. It is released into the bloodstream following myocardial injury, making it a highly specific and sensitive biomarker for cardiac muscle damage. Elevated levels of cTnI are a key indicator of acute myocardial infarction (AMI) and are widely used in the diagnosis and risk stratification of patients with suspected acute coronary syndrome (ACS). Due to its high cardiac specificity and prolonged elevation post-injury, cTnI is considered a gold-standard biomarker for detecting even minor myocardial damage. High-sensitivity assays enable earlier detection of cardiac events, improving clinical decision-making and patient outcomes.

96 well assay